Attendance from
Biopharma & Big Pharma
65%
Europe's Focal Forum for Manufacturing Excellence, Formulation & Outsourcing
3-4 November 2026
Radisson Blu Hotel, London Heathrow, London, United Kingdom
Attendance from
CDMO
15%
Attendance from
Solution/ Technology & Equipment Providers
10%
Attendance from
Research Institutes
5%
Decision Makers
VP / Global Head / Site Head / Head of CMC / Manufacturing
C-Suite / EVP (CEO, COO, CSO, CTO)
Director / Associate Director
Senior Manager / Manager
Scientist / Engineers
Business Development
By Geography
Day 1 | 3 November 2026 |
|
|
|
|
Biologics Manufacturing Strategy
|
Novel Formulation Strategies for Complex Biologics - mAbs, Bispecifics, & ADCs
|
| Networking Break | |
|
Optimising CDMO Partnerships and Technical Transfer
Spotlight: ADC Outsourcing Excellence
|
Adjuvants & Immunostimulatory Technologies - Amplifying Vaccine Potency
|
| Lunch | |
|
Next-Gen Upstream Processing
|
Formulation Supply Chain – From Clinical to Commercial
|
|
Downstream Purification Optimisation
|
Clinical Development, Evidence Generation & Patient Outcomes
|
| Networking Break | |
|
Strategies For Selecting & Managing CDMOs
|
|
|
Industry Roundtables
|
|
| End of Conference Day 1 | |
Day 2 | 4 November 2026 |
|
|
|
|
|
Managing Quality Oversight Across External Manufacturing Networks
|
From Formulation to Device Integration
|
| Networking Break | |
|
AI & Data Analytics for Process Robustness
|
Next-Generation Therapeutics: RNA, Formulation & Process Innovation
|
| Lunch | |
|
Supply Chain Resilience and Logistics
AI Driven Manufacturing
|
Smart Aseptic Fill–Finish
|
|
Supply Chain Resilience and Logistics
|
|
| Networking Break | |
|
Closing Panel Discussion: Future of European Biomanufacturing + Formulation
|
|
| End of Conference | |
DAY 1
3 November 2026
08:50
Chairman’s Welcome Address
Dr Uwe Gottschalk
Operating Partner, Keensight Capital, France
09:00
A Quality Perspective on Building an AI Strategy That Outlives the Technology
- Why most AI efforts stall: chasing each new capability produces a portfolio of orphans, while a multi-year platform bet delivers nothing until it is finished — and is often obsolete before it lands.
- Defining an integrated strategy that survives an accelerating technology landscape — anchored on your processes and your data, so the strategy outlives the tools underneath it.
- Proving it in a live GMP environment: structuring deviation information at the point of capture to cut documentation time today while making quality data usable tomorrow.
- Compounding the return: connecting deviations, CAPAs, controlled documents, audit findings and published inspection outcomes so patterns surface across products, sites and years.
- Holding the line under pressure: validation, grounding and human-in-the-loop designed in from day one, and how to answer the "why aren't we using the newest thing?" question.
Ian Baldacchino
Vice President, Global Head of Internal Manufacturing Quality, UCB, Belgium
Mathias Van den Borre
Head of Digital Innovation, Global Quality, UCB, Belgium
09:25
Topic - TBC
Solution Provider
Inprocess LSP
09:50
Supply Chain - Intelligence to Increase the Volume & Velocity of Decisions (TBC)
- Leveraging real-time data analytics to improve visibility across end-to-end biologics supply networks
- Using AI-driven forecasting to accelerate decision-making on demand shifts, capacity, and inventory
- Integrating cross-functional data streams to reduce bottlenecks and improve responsiveness
- Enhancing risk detection and scenario planning to support faster, more confident supply chain decisions
Niveth Richard
Supply Chain Decision Intelligence Lead, GSK, UK
10:15
Topic- TBC
Dirk Boehm
Site Head DS Penzberg (VP), Roche, Germany
11:40
Building Scalable and Robust Biologics Platforms Through Integrated Process and Formulation Development
-
Building a trusted CMC data foundation as the backbone for faster, more reliable transfers
-
Connecting AI, automation and digital tools across the end-to-end technology-transfer process
-
Translating digital insights into manufacturing readiness, reduced risk and fewer pre-PPQ runs
-
Establishing measurable standards for value tracking, acceleration and continuous improvement
-
Scaling a repeatable approach across products, modalities, sites and partnerships
Filippo Ramondelli
Associate Director - TT & Project Management Lead, Takeda, Italy
11:35
Spotlight: ADC Outsourcing Excellence
Solution Provider
BSP Pharmaceuticals
12:00
De-Risking Tech Transfer and Scale-Up with CDMOs
- Managing successful tech transfer across complex manufacturing processes
- Reducing scale-up risks while maintaining product quality and consistency
- Improving communication and operational alignment between sponsors and CDMOs
- Ensuring supply continuity and manufacturing readiness for commercial demand
Anthony Beaney
Principal Scientist, Lonza Biologics, UK
12:25
Strategic Oversight of ADC External Manufacturing: Strengthening Sponsor–CDMO Collaboration from Tech Transfer to Commercial Supply
- Managing successful tech transfer from development to commercial supply
- Strengthening sponsor–CDMO alignment across ADC manufacturing programs
- Ensuring quality and supply continuity across external manufacturing networks
- Improving operational visibility and governance within complex ADC supply chains
13:50
Unlocking Biologics Manufacturing Potential: Case Studies in Data Science Applications
- Applying data science to optimize upstream and downstream process performance and reduce variability
- Using advanced analytics to identify root causes of batch deviations and improve yield consistency
- Leveraging predictive models to enhance process control, scale-up success, and tech transfer efficiency
- Demonstrating real-world case studies where data-driven insights improved cost, quality, and time-to-market
Shyam Panjwani
Principal Biotech Data Scientist | CMC Statistician | Biologics Manufacturing, Bayer, USA
14:15
Topic - TBC
Michael Palige
Process Development & CMC Lead, Takeda, Austria
14:40
AI-Enabled Downstream Purification Optimisation: Improving Yield, Purity & Process Robustness
- Optimising chromatography and filtration steps using data-driven process modelling and real-time monitoring
- Reducing product loss and impurity breakthrough through improved control of critical process parameters
- Integrating PAT and advanced analytics to enable faster troubleshooting and cycle time reduction
- Enhancing scalability and robustness of purification processes from lab to commercial manufacturing
Gavin Wild
Head of Early Process Sciences, UCB, UK
15:30
Managing CDMO Partnerships Across Formulation & Supply Networks (TBC)
- Selecting the right CDMO partners for formulation development, manufacturing, and commercial supply.
- Establishing governance models that drive performance, transparency, and long-term collaboration.
- Managing supply chain risks, capacity constraints, and business continuity across external networks.
- Using performance metrics and operational reviews to ensure quality, reliability, and on-time delivery.
Karen O'Hanlon
Chief Operating Officer, StablePharma, UK
15:55
Choosing the Right Outsourcing Partner: From Payload to Fill-Finish
- Evaluating CDMO capabilities across the full manufacturing workflow
- Strengthening collaboration and oversight across multi-partner supply chains
Abisola (Abi) Kuforiji
Associate Director-External Manufacturing -Operations lead (EMEA), MSD, Switzerland
16:20
Roundtable Discussion
From Pilot to Scale: What Does Successful AI Adoption Really Look Like in GMP Operations?
Ian Baldacchino
Vice President, Global Head of Internal Manufacturing Quality, UCB, Belgium
Mathias Van den Borre
Head of Digital Innovation, Global Quality, UCB, Belgium
Is Your Data Ready for AI? Building the Foundations for Scalable ML (TBC)
Niveth Richard
Supply Chain Decision Intelligence Lead, GSK, UK
Scaling Biologics Manufacturing for Future Demand (TBC)
Dirk Boehm
Site Head DS Penzberg (VP), Roche, Germany
Maximising drug product manufacturing
Alexander Hempel
Manager Drug Substance Manufacturing, Avethera, Germany
TBC
Valerie Chambard-Benalleg
Vaccine Manufacturing Supply Chain Lead, CEPI, UK
Outsourcing Decisions: In-House Capabilities vs. External Partners (TBC)
Julia Hinteramskogler
Head of Technical Development, Elaris, Austria
Building High-Trust Sponsor-CDMO Relationships
Franz Schnetzinger
VP / Head PAD & QC, AAVantgarde Bio, UK
DAY 2
4 November 2026
08:50
Chairman’s Welcome Address
09:00
Building Robust Quality Governance Across Global CDMO Networks
- Establishing effective quality governance frameworks across global CDMO networks
- Strengthening sponsor–CDMO collaboration through clear accountability, communication, and oversight
- Implementing risk-based approaches to supplier management, audits, and quality performance monitoring
- Maintaining inspection readiness and consistent GMP compliance across outsourced manufacturing operations
Marcelo Castro
Senior Director, Global Biopharma External Supply Operations Quality, Pfizer, Ireland
09:25
Enhancing Visibility and Control in External Manufacturing Quality Systems
- Strengthening quality oversight across complex external manufacturing networks
- Improving real-time visibility and risk management within supplier quality systems
- Aligning sponsor–CDMO quality expectations and governance frameworks
- Leveraging digital tools and data analytics to enhance compliance and operational control
Cathal Gallagher
Senior Director-Head of Quality, External Operations EU, Takeda, Ireland
09:50
Speed to Clinic: Tech Transfer and Phase I Manufacturing in Under 6 Months
Solution Provider
Dr Ashwinkumar V Meru
Head of Global Business Development, Kemwell, India
10:15
Strengthening Quality Oversight Across External Manufacturing Networks
- Standardising GMP and quality systems across CDMO partners for consistent compliance
- Using digital QMS tools for real-time deviation tracking and faster resolution
- Strengthening risk-based audits and supplier qualification across sites
- Driving continuous improvement through CAPA and shared quality KPIs
Jose Martinez Calderon
QA R&D and Commercial Product Development Senior Director, Almirall, Spain
11:10
Data-Driven Biopharma: Integrating Real-World Evidence into Development and Lifecycle Strategy
- Leveraging real-world evidence (RWE) to complement clinical trial data and strengthen regulatory and payer submissions
- Integrating diverse data sources to identify patient subgroups, treatment outcomes, and unmet medical needs
- Using advanced analytics to support lifecycle management, label expansion, and post-market surveillance
- Enabling faster, more informed decision-making across development, commercialization, and market access strategies
11:35
Single-Cell RNA Sequencing (scRNA-seq) Workflow: From Sample to Insight
- Isolating and capturing individual cells using microfluidics or droplet-based platforms for high-resolution profiling
- Performing reverse transcription and library preparation to generate single-cell gene expression datasets
- Sequencing and processing data through bioinformatics pipelines for quality control and alignment
- Clustering and interpreting cellular heterogeneity to identify subpopulations and functional states
Dr Aurelien Bunga
Senior Scientist, Rinri Therapeutics, UK
12:00
Predicting the Future: Kinetic Modelling for Smarter Stability Decisions Across the Pharmaceutical Lifecycle
- De-risking early clinical development through accelerated stability prediction with quantified uncertainty
- Optimising cold chain design and setting evidence-based temperature excursion limits
- Accelerating shelf -life determination and supporting regulatory submissions with GMP-ready outputs
- Enabling real-time stability comparability assessment across batches, sites and manufacturing changes
Dr Warren Roche
Biostatistician, Argenx, Belgium
13:30
Optimising Strategic Network Design through Make vs Buy Decision Frameworks
- Evaluating internal vs outsourced manufacturing capabilities
- Designing flexible and scalable manufacturing networks
- Balancing cost, control, and speed to market
- Managing risks across global production and supply networks
Dr John Bridgeman
Chief Scientific Officer, ImmunoKey, UK
13:55
Vaccine manufacturing networks in Low- and Middle-Income Countries
- Strengthening regional vaccine manufacturing capacity and supply resilience in LMICs
- Building sustainable technology transfer and local manufacturing partnerships
- Overcoming infrastructure, workforce, and regulatory challenges across emerging markets
- Enhancing equitable access through scalable and future-ready vaccine manufacturing networks
Vishal Mukund Sonje
Senior Vaccine Manufacturing Lead, CEPI, UK
14:15
AI-Driven Manufacturing: From Innovation to Implementation (TBC)
- Accelerating the adoption of AI across biopharmaceutical manufacturing
- Overcoming barriers to implementation and organizational readiness
- Ensuring robust decision-making through data-driven manufacturing strategies
- Lessons learned from integrating emerging technologies into development and manufacturing
Tejash Shah
Senior Director, Biopharm CMC Regulatory Affairs, GSK, UK
14:40
How to Build a Procurement Consortium in Africa: Building a Model of Aggregated Input Material Sourcing and Procurement
- Developing collaborative procurement models to strengthen supply chain resilience across African markets
- Aggregating demand to improve supplier access, purchasing power, and supply continuity
- Overcoming regulatory, logistical, and stakeholder challenges in multi-country procurement initiatives
- Lessons learned and best practices for building sustainable public-private procurement partnerships
Valerie Chambard-Benalleg
Vaccine Manufacturing Supply Chain Lead, CEPI, UK
15:05
Panel Discussion
The Future of Biopharma Supply Chains – Building Resilience, Agility & Sustainability
Panelists
Brendan Noone
Senior Director, Global Supply Chain & Strategy, AstraZeneca, Ireland
Dr. Andreea Iftimia-Mander
Head of Analytical and Biological Sciences (SCS1), MHRA, UK
16:00
Panel Discussion
Future of European Biomanufacturing + Formulation
- Europe’s biomanufacturing future depends on scaling advanced facilities while maintaining high regulatory and quality standards.
- Strategic investment in automation, digitalisation, and AI will be critical to offset high operating costs.
- Strengthening local supply chains will improve resilience and reduce dependency on external geographies.
- Collaboration across academia, industry, and CDMOs will accelerate innovation and capacity expansion.
Panelists
Julia Hinteramskogler
Head of Technical Development, Elaris, Austria
Syed Saqib Naqvi
Supply Chain Digital Lead, Amicus Therapeutics, UK
DAY 1
3 November 2026
08:50
Chairman’s Welcome Address
Dr Uwe Gottschalk
Operating Partner, Keensight Capital, France
09:00
Advanced Formulation Strategies for Complex Biologics: mAbs, Bispecifics & ADCs
- How dripping can impact filling process control
- Reported approaches to avoid dripping in a filling process
- Droplet elongation rate as an indicator of solution propensity for dripping
- Impact of surfactants on solution propensity for dripping at the nozzle tip end
Sébastien Dasnoy
Principal Scientist, Injectable Formulation Development, UCB, Brussels
09:25
Crack the Protein Formulation Code with Aunty
- Protein formulation labs face challenges every day: more samples to test, increasingly complex candidates, and shorter timelines.
- Optimizing stability, manufacturability, and developability requires extensive excipient screening across multiple parameters—all in less time than ever before.
- This talk shows how you can use Aunty to speed up formulation studies from weeks to days using high-throughput, multi-attribute characterization in a 96-well SBS-format quartz plate.
- By combining full-spectrum DSF, SLS, and DLS in a single experiment, you can gather all the melting and aggregation data necessary to make faster, more informed decisions while improving efficiency.
- Automation-ready workflows keep grinding out results long after you’ve called it a day.
- We’ll review a DoE-based excipient screen of three antibodies and an enzyme that identified major stability drivers in a single experiment.
- We’ll also peek into colloidal parameters kD* and B22*, as well as freeze/thaw performance to provide a more complete picture of formulation behavior.
Solution Provider
Andre Mueller
Director, Product Manager, Unchained Labs, USA
09:50
New Strategies for Oral Delivery of Biologics
Dr Driton Vllasaliu
Reader in Biotherapeutics Delivery, King’s College London, UK
10:15
Cracking Long-Acting Injectables Translation: Lessons from Small
- Early PK and biocompatibility data for small‑molecule LAIs often fail to predict clinical outcomes, creating a persistent predictability gap.
- The injection site acts as a complex, dynamic system, where depot behavior, tissue response, and absorption are tightly linked.
- Traditional approaches (e.g., IVIVC) are insufficiently predictive, requiring a shift to mechanistic, model‑informed translation.
- Success depends on integrated CMC–PK–clinical strategies that reduce uncertainty early through coordinated design.
- These learnings are relevant to high concentration /complex biologics, where greater molecular complexity further tightens the link between formulation, delivery, and clinical performance.
Marieta Duvnjak
Head Science & Operations in Analytical Research and Development, Novartis, India
11:10
The CMC Leader Driving Vaccines from Development to Real-World Supply
Christine Hägglund
VP CMC Development, Scandinavian Biopharma, Sweden
11:35
Solution Provider
Reserved for Solution Provider
12:00
Advancing Cancer Immunotherapies from Discovery to Clinical Development: Aligning Innovation, Formulation, and Patient Impact
Callum Scott
Senior Vice President, Development, Scancell, UK
12:25
13:50
Strengthening Cold Chain and Distribution Strategies for Complex Biologics and Advanced Therapies
- Ensuring end-to-end cold chain integrity for biologics and advanced therapies through robust temperature monitoring and control systems
- Mitigating distribution risks for temperature-sensitive products via real-time tracking, data visibility, and contingency planning
- Optimizing global logistics networks to support timely, compliant, and scalable delivery of complex therapies
- Strengthening collaboration across supply chain stakeholders to maintain product quality from manufacturing to patient delivery
Kellen LaVigne
Director, Supply Chain & Logistics, AurionBiotech, US
14:15
Implementing an innovative automated tool to speed up quality assessments of clinical and commercial drug product excursions globally
Paul de Goede
Principal Scientist Formulation Development, Johnson & Johnson Innovative Medicine, Netherlands
14:40
Building Long-Term Value in Oncology and Hematology: Medical Affairs as a Strategic Partner from Development to Real-World Adoption
- Embedding Medical Affairs early in development to shape evidence generation and clinical strategy in oncology and hematology
- Supporting cross-functional alignment to translate clinical data into meaningful real-world treatment value
- Driving stakeholder engagement through scientific communication and education across HCPs, payers, and patients
- Leveraging real-world evidence to optimize treatment pathways and sustain long-term therapeutic value
Ridwaan Jhetam
Senior Vice President : Head of Worldwide Medical Affairs Hematology, Bristol Myers Squibb, UK
15:30
Managing CDMO Partnerships Across Formulation & Supply Networks (TBC)
- Selecting the right CDMO partners for formulation development, manufacturing, and commercial supply.
- Establishing governance models that drive performance, transparency, and long-term collaboration.
- Managing supply chain risks, capacity constraints, and business continuity across external networks.
- Using performance metrics and operational reviews to ensure quality, reliability, and on-time delivery.
Karen O'Hanlon
Chief Operating Officer, StablePharma, UK
15:55
Choosing the Right Outsourcing Partner: From Payload to Fill-Finish
- Evaluating CDMO capabilities across the full manufacturing workflow
- Strengthening collaboration and oversight across multi-partner supply chains
Abisola (Abi) Kuforiji
Associate Director-External Manufacturing -Operations lead (EMEA), MSD, Switzerland
16:20
Roundtable Discussion
Formulation as a Commercial Differentiator
Marco Carfagna
Head of Formulation Development & Drug Product Labs, Formycon, Germany
From Immunology Discovery to Clinical Translation: Aligning Early Innovation with Formulation and Development Strateg
Dr John Bridgeman
Chief Scientific Officer, ImmunoKey, UK
From Formulation to Patient: Designing Biologics for Access, Adoption, and Real-World Value
Ahmed Abou Khatwa
Regional Patient Value and Access Director, Takeda, Singapore
From Formulation to Delivery: Designing Patient-Centric Therapeutic Platforms for Advanced Modalities
Darren Pitt
Chief Scientific officer and Co-founder, VisusNano, UK
DAY 2
4 November 2026
08:50
Chairman’s Welcome Address
09:00
Bridging Formulation, Manufacturing, and Process Development in Advanced Cell Therapies
- Integrating formulation, process development, and manufacturing to ensure consistent quality in advanced cell therapies
- Overcoming scale-up and variability challenges while maintaining cell viability and functional potency
- Developing closed, automated, and scalable processes to enable robust and reproducible cell therapy production
- Aligning cross-functional teams early to streamline tech transfer
Hollie Bartley
Director, Process Development, Resolution Therapeutics, UK
09:25
Nebulized IgG: A Combination Product Odyssey
- Phase appropriate solutions
- Innovation: Balancing development speed with program risk
- Combination product mind set: The whole is greater than the parts
Max Corbett
Senior Director, CMC Group Head Biologics and Small Molecule, CSL, Switzerland
09:50
Solution Provider
Reserved for Solution Provider
10:15
Designing the System, Not the Parts: Early CMC and Device Integration in Combination Products
- Integrating CMC and device development early to ensure seamless compatibility between drug product and delivery system
- Designing combination products holistically to optimize performance, usability, and patient-centric administration
- Addressing manufacturability and assembly challenges through aligned drug–device development strategies
- Ensuring regulatory compliance by coordinating CMC, device, and combination product requirements from the outset
Ritupon Gogoi
Director, CMC (Biologics Fill-Finish and Drug-Device Combination Products), Zura Bio, UK
11:10
Driving operational excellence across complex biopharma ecosystems
Dr. Christopher van der Walle
Head of Formulation Science, MHRA, UK
11:35
Turning junk into gems: long non-coding RNAs unlock new therapeutic horizons?
Alessandro Bonetti
Director, AstraZeneca, UK
12:00
Building Scalable and Robust Biologics Platforms Through Integrated Process and Formulation Development
Harsha Reddy
Group Lead - Head Upstream Process Development, CMC Bioprocess Lead, Accord BioPharma, UK
13:30
From Tech Transfer to Commercial Supply: Ensuring Quality in Fill–Finish Operations
Sarah Pasqualinotto
External Site Lead, External Operations (Associate Director), Biogen, Switzerland
13:55
From tech transfer to commercial supply, Digitalisation of the formulation, MSAT leadership in vaccines formulation fill and finish
Laurent Marcellin
VP, Head Of Global Vaccines MSAT, Takeda, Switzerland
14:15
Beyond OEE: Integrating Asset Excellence, Automation and Contamination Control in Pre-Filled Syringe Manufacturing
Tarik Cheema
Asset Excellence Lead Pre-Filled Syringes, Roche, Switzerland
14:40
How to Build a Procurement Consortium in Africa: Building a Model of Aggregated Input Material Sourcing and Procurement
- Developing collaborative procurement models to strengthen supply chain resilience across African markets
- Aggregating demand to improve supplier access, purchasing power, and supply continuity
- Overcoming regulatory, logistical, and stakeholder challenges in multi-country procurement initiatives
- Lessons learned and best practices for building sustainable public-private procurement partnerships
Valerie Chambard-Benalleg
Vaccine Manufacturing Supply Chain Lead, CEPI, UK
15:05
Panel Discussion
The Future of Biopharma Supply Chains – Building Resilience, Agility & Sustainability
- Europe’s biomanufacturing future depends on scaling advanced facilities while maintaining high regulatory and quality standards.
- Strategic investment in automation, digitalisation, and AI will be critical to offset high operating costs.
- Strengthening local supply chains will improve resilience and reduce dependency on external geographies.
- Collaboration across academia, industry, and CDMOs will accelerate innovation and capacity expansion.
Panelists
Brendan Noone
Senior Director, Global Supply Chain & Strategy, AstraZeneca, Ireland
Dr. Andreea Iftimia-Mander
Head of Analytical and Biological Sciences (SCS1), MHRA, UK
16:00
Panel Discussion
Future of European Biomanufacturing + Formulation
- Europe’s biomanufacturing future depends on scaling advanced facilities while maintaining high regulatory and quality standards.
- Strategic investment in automation, digitalisation, and AI will be critical to offset high operating costs.
- Strengthening local supply chains will improve resilience and reduce dependency on external geographies.
- Collaboration across academia, industry, and CDMOs will accelerate innovation and capacity expansion.
Panelists
Julia Hinteramskogler
Head of Technical Development, Elaris, Austria
Syed Saqib Naqvi
Supply Chain Digital Lead, Amicus Therapeutics, UK
BIG PHARMA
Ridwaan Jhetam
Senior Vice President : Head of Worldwide Medical Affairs Hematology
Bristol Myers Squibb
UK
BIG PHARMA
Ahmed Abou Khatwa
Regional Patient Value and Access Director
Takeda
Singapore
CHAIRMAN
Dr Uwe Gottschalk
Operating Partner
Keensight Capital
France
Dr. Christopher van der Walle
Head of Formulation Science
MHRA
UK
Dr. Andreea Iftimia-Mander
Head of Analytical and Biological Sciences (SCS1)
MHRA
UK
BIG PHARMA
Filippo Ramondelli
Associate Director - TT & Project Management Lead
Takeda
Italy
BIG PHARMA
Niveth Richard
Supply Chain Decision Intelligence Lead
GSK
UK
BIG PHARMA
Marcelo Castro
Senior Director, Global Biopharma External Supply Operations Quality
Pfizer
Ireland
BIG PHARMA
Paul de Goede
Principal Scientist Formulation Development
Johnson & Johnson Innovative Medicine
Netherlands
BIG PHARMA
Shyam Panjwani
Principal Biotech Data Scientist | CMC Statistician | Biologics Manufacturing
Bayer
USA
BIG PHARMA
Tarik Cheema
Asset Excellence Lead Pre-Filled Syringes
Roche
Switzerland
BIG PHARMA
Marieta Duvnjak
Head Science & Operations in Analytical Research and Development
Novartis
India
BIG PHARMA
Tejash Shah
Senior Director, Biopharm CMC Regulatory Affairs
GSK
UK
BIG PHARMA
Dirk Boehm
Site Head DS Penzberg (VP)
Roche
Germany
BIG PHARMA
Max Corbett
Senior Director, CMC Group Head Biologics and Small Molecule
CSL
Switzerland
BIG PHARMA
Sarah Pasqualinotto
External Site Lead, External Operations (Associate Director)
Biogen
Switzerland
BIG PHARMA
Laurent Marcellin
VP, Head Of Global Vaccines MSAT
Takeda
Switzerland
BIG PHARMA
Alessandro Bonetti
Director
AstraZeneca
UK
BIG PHARMA
Brendan Noone
Senior Director, Global Supply Chain & Strategy
AstraZeneca
Ireland
BIG PHARMA
Cathal Gallagher
Senior Director-Head of Quality, External Operations EU
Takeda
Ireland
%20Kuforiji.png)
BIG PHARMA
Abisola (Abi) Kuforiji
Associate Director-External Manufacturing -Operations lead (EMEA)
MSD
Switzerland
Sébastien Dasnoy
Principal Scientist, Injectable Formulation Development
UCB
Brussels
Ian Baldacchino
Vice President, Global Head of Internal Manufacturing Quality
UCB
Belgium
Mathias Van den Borre
Head of Digital Innovation, Global Quality
UCB
Belgium
Gavin Wild
Head of Early Process Sciences
UCB
UK
Dr John Bridgeman
Chief Scientific Officer
ImmunoKey
UK
Hollie Bartley
Director, Process Development
Resolution Therapeutics
UK
Kellen LaVigne
Director, Supply Chain & Logistics
AurionBiotech
US
Christine Hägglund
VP CMC Development
Scandinavian Biopharma
Sweden
Jose Martinez Calderon
QA R&D and Commercial Product Development Senior Director
Almirall
Spain
Ritupon Gogoi
Director, CMC (Biologics Fill-Finish and Drug-Device Combination Products)
Zura Bio
UK
Alexander Hempel
Manager Drug Substance Manufacturing
Avethera
Germany
Dr Aurelien Bunga
Senior Scientist
Rinri Therapeutics
UK
Marco Carfagna
Head of Formulation Development & Drug Product Labs
Formycon
Germany
Vishal Mukund Sonje
Senior Vaccine Manufacturing Lead
CEPI
UK
Darren Pitt
Chief Scientific officer and Co-founder
VisusNano
UK
Dr Warren Roche
Biostatistician
Argenx
Belgium
Dr Jason Beckwith
Leader in Residence
University of Leeds
UK
Harsha Reddy
Group Lead - Head Upstream Process Development, CMC Bioprocess Lead
Accord BioPharma
UK
Dr Driton Vllasaliu
Reader in Biotherapeutics Delivery
King’s College London
UK
Callum Scott
Senior Vice President, Development
Scancell
UK
Anthony Beaney
Principal Scientist
Lonza Biologics
UK
Andre Mueller
Director, Product Manager
Unchained Labs
USA
Valerie Chambard-Benalleg
Vaccine Manufacturing Supply Chain Lead
CEPI
UK
Julia Hinteramskogler
Head of Technical Development
Elaris
Austria
Franz Schnetzinger
VP / Head PAD & QC
AAVantgarde Bio
UK
Karen O'Hanlon
Chief Operating Officer
StablePharma
UK
Dr Ashwinkumar V Meru
Head of Global Business Development
Kemwell
India
BIG PHARMA
Michael Palige
Process Development & CMC Lead
Takeda
Austria
Syed Saqib Naqvi
Supply Chain Digital Lead
Amicus Therapeutics
UK
GOLD
BRONZE
EXHIBITION & NETWORKING
ASSOCIATE
Thought Leadership Speaking
Panel Participation
Solution Showcases
Engagement and Visibility Opportunities
Branding and Digital Visibility
Exclusive Networking
Dr Heiner Apeler
VP Head of Biologics Development
Bayer
Germany
The Biologics and CGT Manufacturing DACH conference 2026 was very well planned and coordinated. It provided high-quality talks for staying up-to-date in our industry and I specifically enjoyed the time for networking.
John Bridgeman
CSO
Immunokey
UK
Thanks for the invite to speak at the event. It was a really enjoyable meeting and a great opportunity to present our work to the community. Identifying key partners for ImmunoKey’s development plan is a critical aspect of getting our therapies to patients; the CGT and Biologics Manufacturing DACH meeting offered us the opportunity to engage with key CDMOs who can help us achieve this goal.
Dennis Stelljes
Associate Director, Strategic Sourcing & Procurement, Biologics External Manufacturing
BMS
Switzerland
Just back from an incredible time at the Biologics Manufacturing DACH congress! I have to be honest - as someone in Procurement, some of the deep-dives into Cell & Gene and biologics development were definitely above my scientific capabilities! However, the exchange of knowledge was fantastic, and it was a privilege to learn from such brilliant minds. A true highlight was the fantastic collaboration with Christopher Pawlak (PhD) . I had the privilege of co-hosting a round table with him focused on the impact of tariffs in the biopharma world. Christoph, thank you for the partnership - it was a truly dynamic discussion! 🤝 One of my biggest takeaways is that we have officially entered the era of "The Great Reshoring". We are moving past the days when drug manufacturing decisions were purely scientific; they are now deeply geopolitical. As we discussed in our round table, we can no longer just react to change. We have to treat scenario planning like a muscle that we train constantly to design for volatility. The event really hit home how much our world is changing - from the incredible progress in biologics manufacturing to the AI evolution. I’m excited to see how we can implement these insights to build resilience and benefit BMS biologics manufacturing. Back to my desk, I will start with socializing the learnings with my colleagues. A huge thank you to Drishti G. for the flawless organization and to Noel Murphy for approving the trip and supporting this critical learning opportunity!
Dr Andrew Kelly
Director, Manufacturing Technology
BMS
Ireland
Really well organised conference with great attendees and high engagement - I was delighted to have taken the time to attend and really enjoyed sharing my thoughts on Accelerating Biologics Pipeline and ensuing discussion. Thank you to all organisers and facilitators
Dr Thomas Villiger
Professor of Bioprocess Technology
University of Applied Sciences and Arts Northwestern Switzerland FHNW
Switzerland
A fantastic deep dive into the DACH region’s CGT landscape. This conference made one thing clear: efficacy is proven, but industrialization is the new frontier. To truly move the needle, we must look beyond the lab and focus on scaling automation, streamlining supply chains, and tackling COGS. The diversity of voices - from large corporations, to tech suppliers and academic pioneers - provided a 360-degree view of the manufacturing challenges we must solve together.
Brian O'Connor
VP Global Quality
Orchard Therapeutics
UK
Thanks for the invite. The conference was really excellent, due to the caliber and engagement of the attendees.
Alvaro Avivar-Valderas
Associate Director - Cell Therapy Technology & Product Engine
Takeda
Spain
Thanks for putting this together! I enjoyed the discussions, atmosphere and engagement of participants. Great to be there!
Steffen Schulze
Strategic Analytics & Business Analytics Lead
Roche
Switzerland
I thoroughly enjoyed attending the CGT Manufacturing DACH 2026 by IMAPAC. The program featured exceptionally industry-relevant talks that provided deep insights into the current landscape. Beyond the sessions, the networking opportunities were top-tier, thanks to the high caliber of participants.
Terry Gray
Field Marketing Manager
Merck
I had the pleasure of collaborating with the IMAPAC team during the Irish leg of the Biologics World event in February 2026. The organisers were exceptionally receptive and helpful, ensuring a seamless experience throughout the planning, exhibition logistics, partnering sessions, and sponsor visibility. Their proactive approach in connecting us with potential partners significantly enhanced our ROI. We are already exploring future opportunities to work with the IMAPAC team.
Warren Roche
Senior Statistical Expert
Sanofi
Ireland
Thank you for your email and organising this wonderful event. It was a pleasure to participate. Congratulations on organising this event. It was a wonderful opportunity to present our work and to collaborate with others in the area. Looking forward to your next event
Michael Inglis
Head of Manufacturing Sciences, Analytical Technologies
Chiesi Farmaceutici Global Rare Disease
Ireland
Thank you, it was a pleasure meeting you, and your enthusiasm made it an engaging and positive event.
I hope we have opportunity to connect again in the future.
Shada Warreth
Global Partnerships Implementation Senior Manager
NIBRT
Ireland
Well done on a very informative and successful event.
Radisson Blu Hotel, London Heathrow
140 Bath Road, Harlington, Hayes UB3 5AW, UK
Travel Options
By London Underground
From Heathrow Airport
Taxi or Ride-Hailing
By Car
From Other UK Cities
Accommodation Options
Explore recommended hotels near the venue.
Exclusive delegate hotel rate
Please note: the conference registration fee does not include hotel accommodation or travel expenses.
IMAPAC has secured an exclusive discounted room rate for conference delegates. Use one of the booking options below and quote the conference block code where applicable.
Please complete your booking by 03 October 2026 to secure the discounted conference rate. Bookings made after the cut-off date are subject to hotel availability and may be charged at the prevailing room rate.
Standard Double Room
- Single occupancy£129.00
- Double occupancy£139.00
Rates include full breakfast.
Venue Hotel
Special Rate
Radisson Blu Hotel, London Heathrow
140 Bath Road, Hayes, Middlesex, UB3 5AW
venue for this event
To book a room at this hotel, please click the button below
London Heathrow Mariott Hotel
Bath Road Heathrow, Airport, Hayes UB3 5AN
4 minute walk from venue
To book a room at this hotel, please click the button below
Ibis Style London Heathrow Airport
272 Bath Rd, London UB3 5AY
8 minute walk from venue
To book a room at this hotel, please click the button below
Premier Inn London Heathrow
15 Bath Rd, London TW6 2AB
5 minute drive from venue
To book a room at this hotel, please click the button below
Please find the booth allocation in the table below.
3
Briggs of Burton
4
Alfa Laval
7
Greenfield Global
11
QuickSTAT
12
BSP Pharmaceuticals
14
AsTec Chemicals
17
Unchained Labs
19
Inprocess LSP
18
Kemwell Biopharma
